Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study

BACKGROUND: Human telomerase reverse transcriptase (hTERT) is an antigen that may represent a target for a novel anti-cancer strategy. A pilot, phase I study tested the safety and feasibility of a prime-boost immunization regimen based on V935, an adenoviral type 6 vector vaccine expressing a modifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aurisicchio, Luigi, Fridman, Arthur, Mauro, David, Sheloditna, Rose, Chiappori, Alberto, Bagchi, Ansuman, Ciliberto, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993365/
https://www.ncbi.nlm.nih.gov/pubmed/32000810
http://dx.doi.org/10.1186/s12967-020-02228-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993365/
https://www.ncbi.nlm.nih.gov/pubmed/32000810
http://dx.doi.org/10.1186/s12967-020-02228-9

Ejemplares similares